Journal article

Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register

FJE Vajda, JE Graham, AA Hitchcock, TJ O'Brien, CM Lander, MJ Eadie

SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | W B SAUNDERS CO LTD | Published : 2010

Abstract

Lamotrigine (LTG) is increasingly being prescribed in pregnancy for women with epilepsy in place of valproate (VPA), because of the teratogenic risks associated with the latter. It is therefore important to know the teratogenic hazard associated with LTG, relative to VPA and to other commonly used antiepileptic drugs (AEDs). Data from the Australian Register of Antiepileptic Drugs in Pregnancy was examined to determine the incidence of teratogenicity determined 1 year from completion of pregnancy in women who took AEDs in monotherapy during pregnancy. Compared with a 3.4% malformation incidence in women who took no AEDs (N = 118), the incidences for LTG (N = 243), carbamazepine (CBZ) (N = 30..

View full abstract

Grants

Funding Acknowledgements

We wish to acknowledge the support of our colleagues, medical and non-medical, both in referring patients and increasing patient awareness of the Register. We thank the Scientific Advisory Board and the Ethical Research Committees of St. Vincent's Hospital, Monash Medical Centre, the Royal Melbourne Hospital and other institutions for their assessments of the study. The Australian Register is indebted for support to the Epilepsy Society of Australia, The Victorian Epilepsy Foundation, Epilepsy Australia and also for generous financial support from the pharmaceutical industry, including Sanofi-Aventis, UCB Pharma, Janssen-Cilag, Novartis and Pfizer, and past support from Glaxo.